Clinical Trials Browser

Non-Muscle Invasive Bladder Neoplasms × tislelizumab × Clear all

NCT05957757 2023-08-31

RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Expression

Phase 2 Recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT05580354 2022-10-14

Safety and Efficacy of BCG Combined With Tislelizumab for BCG-untreated Patients With High-risk Non-muscle Invasive Bladder Cancer

Phase 4 Unknown

Non-Muscle Invasive Bladder Neoplasms